{"id":"W4389465400","doi":"10.1212/wnl.92.15_supplement.p3.2-031","title":"Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis (P3.2-031)","year":2019,"lang":"en","type":"article","venue":"Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Pediatrics; Oncology; Internal medicine; Dermatology; Immunology; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004862926,0.0001506684,0.0003748148,0.00008064524,0.00001062335,0.000003638745,0.00004839151,0.000110416,0.00007961642],"category_scores_gemma":[0.00003200468,0.0001160702,0.00004928536,0.0001801302,0.0002186167,0.00007040562,0.00003449731,0.0001725939,0.000007748882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007686883,"about_ca_system_score_gemma":0.00005594797,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002232052,"about_ca_topic_score_gemma":0.0001713504,"domain_scores_codex":[0.9987313,0.0001389882,0.00028686,0.0004017979,0.000184313,0.0002567422],"domain_scores_gemma":[0.9994543,0.00004243627,0.0001140693,0.0002884427,0.00004282523,0.00005793119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02880122,0.002775,0.9438215,0.00007070512,0.000009466531,0.00003997643,0.0003440705,0.00002021137,0.0008652743,7.027608e-7,0.00001004655,0.02324184],"study_design_scores_gemma":[0.01049747,0.01245996,0.9763729,0.00007280216,0.00001443063,0.000006385596,0.0000225995,0.00006536346,0.0001491716,0.000004624779,0.000246804,0.0000874844],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977286,0.0001000475,3.663671e-7,0.0002830953,0.0001741956,0.001598824,0.000009151972,0.00002167595,0.00008397984],"genre_scores_gemma":[0.9994218,0.00002483478,0.00007496081,0.0002112656,0.0000149177,0.0001781068,0.00003561147,0.0000216825,0.00001680831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03255142,"threshold_uncertainty_score":0.4733206,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01085781988190639,"score_gpt":0.2306196629575331,"score_spread":0.2197618430756267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}